Literature DB >> 16468643

[The effects of 20(R)-Rg3 on lung carcinoma A549 cell line and endogenous VEGF secreted by tumor cells].

Ming-wei Chen1, Lan Yang, Lei Ni, Chen Huang.   

Abstract

OBJECTIVE: To assess the effect of 20(R)-Rg3 on the inhibition of angiogenesis of lung cancer and explore its role in the change of endogenous VEGF secreted by A549 tumor cells themselves.
METHODS: A549 tumor cells were cultured with different concentrations of 20(R)-Rg3(10(-7) mol/L, 10(-6) mol/L, 10(-5) mol/L and 10(-4), mol/L), the VEGF contents were detected by ELASA method after 24 h, 48 h and 72 h. Cellular proliferation was detected by MTT method, and apoptosis was detected with flow cytometry.
RESULTS: It was found that Rg3 had no significant inhibitory effect on the proliferation of A549 cells. The apoptosis rate was 29.8% after the cells being interfered with Rg3 at 3 x 10(-5) mol/L for 120 h. The levels of VEGF in the groups of Rg3 at 10(-5) mol/L and 10(-4) mol/L were lower than that in the contrast group (P < 0.05). The level of VEGF in the group of 10(-4) mol/L was lower than that in the group of 10(-7) mol/L and group of 10(-6) mol/L, and it was lower after 72 h of interference than that after 24 h and 48 h of interfernce.
CONCLUSION: With the action of 20 (R)-Rg3, the level of VEGF secreted by A549 tumor cells themselves declined; the apoptosis of A549 tumor cells increased, especially at higher concentration and longer action time of Rg3. This might be one of the antiangiogenesis mechanisms of 20(R)-Rg3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16468643

Source DB:  PubMed          Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-173X


  3 in total

1.  Three new triterpenoids from Panax ginseng exhibit cytotoxicity against human A549 and Hep-3B cell lines.

Authors:  Hai-Ying Ma; Hui-Yuan Gao; Jian Huang; Bo-Hang Sun; Bo Yang
Journal:  J Nat Med       Date:  2012-04-12       Impact factor: 2.343

2.  Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review.

Authors:  Tao Xu; Zhichao Jin; Yuan Yuan; Huamin Wei; Xinyao Xu; Shulin He; Shuntai Chen; Wei Hou; Qiujun Guo; Baojin Hua
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-05       Impact factor: 2.629

3.  Vitexicarpin acts as a novel angiogenesis inhibitor and its target network.

Authors:  Bo Zhang; Lu Liu; Shiwen Zhao; Xu Wang; Liyang Liu; Shao Li
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-12       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.